Literature DB >> 1347947

Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.

R Lupu1, R Colomer, B Kannan, M E Lippman.   

Abstract

The erbB-2 oncogene encodes a 185-kDa transmembrane protein that has been suggested to be a growth factor receptor. We have previously identified and purified a 30-kDa growth factor (gp30) that is a ligand for the p185erbB-2 protein that at high concentrations induces growth inhibition of cells with erbB-2 amplification. We now report the purification and characterization of a protein from SKBr-3 human breast cancer cells with a molecular mass of 75 kDa (p75) that is a p185erbB-2 ligand. An affinity column coupled to the extracellular domain of p185erbB-2 was used for the purification. We found that p75 induced tyrosine phosphorylation of the erbB-2 oncoprotein, as determined by in vivo and in vitro phosphorylation and phosphoamino acid analysis. p75, as well as gp30, stimulated cell proliferation and colony formation of cells overexpressing erbB-2. The specificity of this effect was confirmed by showing that the antiproliferative effects of soluble erbB-2 extracellular domain were reversed by either p75 or gp30. p75 did not show binding to the epidermal growth factor receptor and had no growth effects on cells overexpressing epidermal growth factor receptor. These data show that SKBR-3 cells, which exhibit erbB-2 amplification and overexpression, secrete a growth factor that binds and activates p185erbB-2 specifically.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347947      PMCID: PMC48642          DOI: 10.1073/pnas.89.6.2287

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Generation of monoclonal antibodies against phosphotyrosine and their use for affinity purification of phosphotyrosine-containing proteins.

Authors:  A R Frackelton; M Posner; B Kannan; F Mermelstein
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.

Authors:  T Wada; X L Qian; M I Greene
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

3.  An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.

Authors:  B C Langton; M C Crenshaw; L A Chao; S G Stuart; R W Akita; J E Jackson
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

4.  Biochemical analysis of the ligand for the neu oncogenic receptor.

Authors:  Y Yarden; E Peles
Journal:  Biochemistry       Date:  1991-04-09       Impact factor: 3.162

5.  Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens.

Authors:  P J Kushner; E Hort; J Shine; J D Baxter; G L Greene
Journal:  Mol Endocrinol       Date:  1990-10

6.  Human microvascular endothelial cells express receptors for platelet-derived growth factor.

Authors:  J G Beitz; I S Kim; P Calabresi; A R Frackelton
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

7.  Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.

Authors:  T Kawamoto; J Mendelsohn; A Le; G H Sato; C S Lazar; G N Gill
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

8.  p185neu expression in human lung adenocarcinomas predicts shortened survival.

Authors:  J A Kern; D A Schwartz; J E Nordberg; D B Weiner; M I Greene; L Torney; R A Robinson
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

9.  Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.

Authors:  D B Weiner; J Nordberg; R Robinson; P C Nowell; A Gazdar; M I Greene; W V Williams; J A Cohen; J A Kern
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

10.  Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.

Authors:  C I Bargmann; R A Weinberg
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  23 in total

Review 1.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation.

Authors:  N Kiyokawa; D H Yan; M E Brown; M C Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

4.  c-erb-B2 expression and response to treatment in metastatic breast cancer.

Authors:  W R Bezwoda
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 5.  Human breast cancer cell lines as models of growth regulation and disease progression.

Authors:  S P Ethier
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-01       Impact factor: 2.673

6.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 7.  The significance of heregulin in breast cancer tumor progression and drug resistance.

Authors:  R Lupu; M Cardillo; C Cho; L Harris; M Hijazi; C Perez; K Rosenberg; D Yang; C Tang
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines.

Authors:  H Jinno; M Ueda; K Enomoto; T Ikeda; P Kyriakos; M Kitajima
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

9.  Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.

Authors:  L Bangalore; A J Tanner; A P Laudano; D F Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.

Authors:  S S Bacus; D Chin; Y Yarden; C R Zelnick; D F Stern
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.